Versaflex HC - Syringe Plunger - English SYRINGE MANUFACTURER D I S P O S A B L E S Y R I N G E P L U N G E R • USP VI and ISO 10993-4,5 compliant • Sterilize by gamma & EtO • Long-term sealing performance • Low coefficient of friction (COF) • Consistent performance across barrel sizes • Provided a formulated solution that met rigorous medical application requirements • Improved global supply continuity • Increased process efficiency by replacing previous thermoset material with TPE Versaflex™ HC 2110-57B KEY REQUIREMENTS WHY AVIENT?

SOFT TOUCH + COLORABILITY FOOT WE AR ACCE S S ORY BRAND F O O T W E A R I N S E R T • Low durometer with good processability • Optimal cushioning with high elasticity • Non-tacky feel • Excellent colorability • Customized a formulation to achieve super soft gel performance without a tacky finish • Provided material with sufficient cushioning and elasticity for all-day comfort • Optimized lead time and stable supply with local inventory Versaflex™ Customized TPE KEY REQUIREMENTS WHY AVIENT?

SYRINGE MANUFACTURING D I S P O S A B L E S Y R I N G E T I P C A P • Excellent sealing and resealing performance • No DEHP or natural rubber latex added during processing • Can be sterilized by EtO • Compliance with ISO 10993-4&5, USP Class VI Dynaflex™ Thermoplastic Elastomer KEY REQUIREMENTS WHY AVIENT?

COSMETIC PACKAGING OEM L I P G L O S S T I P B R U S H • Good chemical resistance • Shore 40A hardness at a 60-degree angle • Natural/transparent color • Can be flocked • Delivered a formulation with good chemical resistance to oil in long-term environments • Provided an easy-to-mold TPE and replaced TPU/TPEE with a better soft touch feel • Offered good adhesion with an epoxy resin glue with no impact on the flocking process Versaflex™ Thermoplastic Elastomers KEY REQUIREMENTS WHY AVIENT?

R E F O R M D E S I G N L A B B I O - B A S E D D E S I G N F U R N I T U R E • Matt black color in cellulose fiber filled PLA • 3D-printable material • Possible outdoor use • Fast development to adapt to online requests • Developed custom products that fulfill color, appearance, UV stabilization and material requirements • Provided fast support to answer evolving online demands • Offered small and flexible quantities and suggestions for further colors OnColor™ custom masterbatch and engineered material KEY REQUIREMENTS WHY AVIENT?

WOUND CARE MA NUFAC TURER S E L F - A D H E S I V E B A N D A G E S • Provided aqueous dispersions that are safe for uses in contact with human skin and produce low levels of VOCs • Offered high antioxidant performance to protect bandages from degradation and improve storage time • Collaborated to deliver effectively and efficiently with accelerated development cycles and streamlined operations Aquamix Additive Formulations WHY AVIENT?

MC-60454AB ORANGE R7061 MC-60946PE ORANGE MC-60958PE ORANGE 021C

Avient corporation first quarter 2023 results AVIENT CORPORATION I N V E S T O R P R E S E N T A T I O N (NYSE: AVNT) F E B R U A R Y 2 0 2 4 D I S C L A I M E R Forward-Looking Statements Certain statements contained in or incorporated by reference into this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Continue fostering our Great Place to Work® culture Strategic Objectives Long Term Growth Rates Growth Drivers $340 $455 $790 $1,135 2016 2018 2020 2023 $51 $84 $212 $645 2016 2018 2020 2023 $108 $113 $231 $230 2016 2018 2020 2023 $265 $358 $726 $725 2016 2018 2020 2023 8-12% 8-10% 8-10% 5% Sustainable Solutions Composites Healthcare Asia/Emerging Regions Profitable Growth Great Place to Work 5.4% 10.9% 16.0% 2006 2014 2023 EBITDA Margins $0.14 $1.93 $2.36 2006 2014 2023 Adjusted EPS TOP -T IE R S US TAINABIL IT Y P E RF ORM ANCE AND RE COGNIT ION Industry Sustainability Standards ESG Ratings Performance 1 2 4 87th 94th percentile 5 Avient CDP Score: A- F E B R U A R Y 1 4 , 2 0 2 4 W E B C A S T P R E S E N T AT I O N DR. AS HIS H KHANDP UR P R E S I D E N T & C E O 7 8 PORTFOLIO TRANSFORMATION 8 7% 46% 66% 87% 100% 0% 20% 40% 60% 80% 100% 2005 2010 2015 2020 2023 % o f A dj us te d E B IT D A Commodity JVs Distribution Performance Products & Solutions Specialty Businesses Adjusted EBITDA from Specialty Applications SUSTAINABILITY AS A GROWTH DRIVER 9 LONG-TERM REVENUE GROWTH DRIVERS Sustainable Solutions Composites, Healthcare, Asia / LATAM Overlap Other 60%+ Key Growth Drivers Total Company Revenue Growth Drivers Long-Term Growth Rate Sustainable Solutions 8–12% Composites 8–10% Healthcare 8–10% Asia / LATAM 5% Other 0–2% Avient 6% END MARKET OBSERVATIONS ( % O F C O M PA N Y S A L E S ) ENERGY 5% DEFENSE 7% TELECOMMUNICATIONS 4% HEALTHCARE 7% 10 TRANSPORTATION 10% INDUSTRIAL 16% BUILDING & CONSTRUCTION 9% CONSUMER 19% PACKAGING 23% 11 REGIONAL OBSERVATIONS ( % O F C O M PA N Y S A L E S ) 11 US & Canada Latin America EMEA Asia 41% 36% 18% 5% Q 4 2 0 2 3 R E S U L T S Q4 2023 PERFORMANCE VS.

Microsoft PowerPoint - AVNT Q2 2022 Earnings Presentation AVIENT CORPORATION S E C O N D Q U A R T E R 2 0 2 2 R E S U L T S (NYSE: AVNT) J U L Y 2 6 , 2 0 2 2 D I S C L A I M E R 2 Forward-Looking Statements Certain statements contained in or incorporated by reference into this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. S E C O N D Q U A R T E R 2 0 2 2 R E S U L T S $122 $134 2021 2022 $0.87 $0.98 2021 2022 Q2 2022 PERFORMANCE ( T O TA L C O M PA N Y ) 4 Sales Adjusted Operating Income $1,235 $1,302 2021 2022 + 5% Adjusted EPS + 10% + 13% (in millions) (in millions) (+ 10% excluding FX) (+ 16% excluding FX) (+ 20% excluding FX) Q2 2022 SEGMENT PERFORMANCE 5 CAI $624 $649 Sales ($ in millions) SEM Distribution $86 $94 Operating Income + 4% + 9% $404 $443 Sales $24 $27 Operating Income + 10% + 13% (1) $241 $244 Sales $37 $37 Operating Income + 1% Flat (+ 10% excluding FX) (+ 16% excluding FX) (+ 6% excluding FX) (+ 3% excluding FX) Q2 2021 $1,235 $122 Sustainable Solutions 17 7% 7 Healthcare 23 14% 5 Composites (ex Outdoor High Performance) 10 20% 4 Growth in Asia / LATAM 5 3% 1 Other 69 11% 5 Sub-total $1,359 10% $144 Outdoor High Performance Impact (9) (5) Wage Inflation and Overtime (7) Other Supply Chain Costs (2) Clariant Color Integration Synergies 7 Incentives, Other Employee Costs 4 FX (48) (7) Q2 2022 $1,302 5% $134 Q2 2022 SALES AND OPERATING INCOME ( T O TA L C O M PA N Y ) 6 Sales Growth Rate Adjusted Operating Income$ millions Adjusted EBITDA Q2 EBITDA BRIDGE 7 Price increases more than offsets raw material and supply chain impacts Q2 2021 $ 159 Demand (29) $ millions CAI: Price / Mix 87 Inflation (58) SEM: Price / Mix 36 Inflation (24) Distribution: Price / Mix 45 Inflation (41) Net Price Benefit 45 Wage Inflation and Overtime (7) Other Supply Chain Costs (2) Clariant Color Integration Synergies 7 Incentives, Other Employee Costs 4 FX (7) Q2 2022 $ 170   China Lockdowns / Russia Impact $ (14) Outdoor High Performance (5) Transportation (5)  8 Q2 '21 Adjusted EPS 0.87$ Color, Additives and Inks 0.11 Specialty Engineered Materials 0.01 Distribution 0.03 Corporate Costs 0.01 F/X (0.05) Segment OI 0.11$ Interest Expense 0.03 Tax Rate (0.03) Q2 '22 Adjusted EPS 0.98$ Q2 EPS BRIDGE Key Updates • Provided progress on 2030 Sustainability Goals • Emphasized commitment to U.N. Annual Purchases RAW MATERIAL AND SUPPLY CHAIN UPDATE Based on 2021 purchases, excludes Distribution business SEGMENT DATA U.S. & Canada 50% EMEA 25% Asia 16% Latin America 9% 2021 SEGMENT, END MARKET AND GEOGRAPHY GEOGRAPHY REVENUESEGMENT FINANCIALS Consumer 23% Packaging 19% Industrial 16% Building and Construction 10% Telecommunications 4% Energy 2% END MARKET REVENUE (1) Total company sales and adjusted EBITDA of $4,819M and $581M, respectively, include intercompany sales eliminations and corporate costs $2,402M $409M $919M $164M $1,631M $94M Sales EBITDA Distribution Specialty Engineered Materials Color Additives and Inks $581M$4,819M (1) Transportation 11% Healthcare 15% 24 Packaging 34% Consumer 21% Healthcare 8% Industrial 16% Building & Construction 10% Transportation 9% Energy 1% Telecommunications 1% C O L O R , A D D I T I V E S & I N K S 2 0 2 1 R E V E N U E | $ 2 . 4 B I L L I O N US & Canada 32% EMEA 40% Asia 21% Latin America 7% END MARKET REGION 25 All charts reflect 2021 financials S P E C I A L T Y E N G I N E E R E D M A T E R I A L S Consumer 27% Healthcare 10% Packaging 7% Telecommunications 16% Transportation 11% Industrial 11% Building & Construction 11% Energy 7% 2 0 2 1 R E V E N U E | $ 9 1 9 M I L L I O N END MARKET US & Canada 55% EMEA 25% Asia 20% REGION 26 All charts reflect 2021 financials D I S T R I B U T I O N Healthcare 26% Consumer 23% Packaging 5% Industrial 20% Transportation 16% Building and Construction 8% Energy 1% Telecommunications 1% US & Canada 80% Asia 3% Latin America 17% END MARKET REGION K E Y S U P P L I E R S 2 0 2 1 R E V E N U E | $ 1 . 6 B I L L I O N 27 All charts reflect 2021 financials T O T A L C O M P A N Y R E G I O N A L S A L E S B Y E N D M A R K E T Packaging 30% Consumer 26%Healthcare 13% Industrial 14% Building & Construction 5% Telecommunications 2% Energy 2% Asia (16% of sales) Transportation 8% Packaging 32% Consumer 13% Healthcare 5% Industrial 17% Building & Construction 12% Telecommunications 5% Energy 4% EMEA (25% of sales) Transportation 12% 28 Consumer 25% Healthcare 19% Packaging 10% Industrial 17% Building & Construction 10% Telecommunications 4% Energy 2% US & Canada (50% of sales) Transportation 13% Packaging 38% Consumer 33% Healthcare 8% Industrial 10% Building & Construction 5% Telecommunications 1% LATAM (9% of sales) Transportation 5% All charts reflect 2021 financials Reconciliation of Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except for per share data) Senior management uses comparisons of adjusted net income from continuing operations attributable to Avient shareholders and diluted adjusted earnings per share (EPS) from continuing operations attributable to Avient shareholders, excluding special items, to assess performance and facilitate comparability of results.

Medical textile manufacturer LEARN MORE MEDICAL TEXTILE MANUFACTURER S U R G I C A L D R A P E S & G O W N S • Pre-tested for ISO 10993 biocompatibility standard • Available in standard blue or other customized colors • Compatible with ETO sterilization • Suitable for use in non-woven SMS spunbond layer • Offered standard blue and custom colors such as green • Pre-tested raw materials for biocompatibility ISO10993 standard • Manufactured under ISO 13485 certified medical sites with change control in place MevopurTM Healthcare Colorants and Formulations KEY REQUIREMENTS WHY AVIENT?